SEI Investments
ADAP

SEI Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

SEI Investments’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-54,824
Closed -$7.13K – 3120
2025
Q3 		$7.13K Hold
54,824
– – ﹤0.01% 2814
2025
Q2 		$13.1K Hold
54,824
– – ﹤0.01% 2783
2025
Q1 		$10.8K Buy
+54,824
New +$28.4K ﹤0.01% 2749
2023
Q2 		– Sell
-47,409
Closed -$51.7K – 2666
2023
Q1 		$51.7K Sell
47,409
-39,316
-45% -$60.9K ﹤0.01% 2623
2022
Q4 		$127K Buy
86,725
+55,438
+177% +$89.8K ﹤0.01% 2420
2022
Q3 		$34K Buy
+31,287
New +$57.5K ﹤0.01% 2635

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SEI Investments's ADAP Position: Q4 2025 in Review

SEI Investments sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 54,824 shares — an estimated $7.13K sold.

SEI Investments first reported a position in ADAP in Q3 2022 and held it in 6 quarters. The position peaked at $127K in Q4 2022. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • SEI Investments reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SEI Investments sold 54,824 Adaptimmune Therapeutics shares in Q4 2025, an estimated $7.13K.
  • SEI Investments first reported a position in Adaptimmune Therapeutics in Q3 2022 and held it in 6 quarters.
  • SEI Investments's Adaptimmune Therapeutics position peaked at $127K in Q4 2022.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on SEI Investments's 13F filing for Q4 2025, filed 13 Feb 2026.